Toxicity of psychedelic drugs
Toxicological Risk Assessment and Multi-System Health Impacts from Exposure, Page: 545-556
2021
- 10Citations
- 14Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The drugs of abuse market has been steadily increasing, and new classes of psychoactive substances appear every year, with potential addictive properties and side effects. Healthcare providers need to be aware of the toxicodynamic and toxicokinetic properties of these drugs for prevention, diagnosis and treatment of emergency cases. Serotonergic hallucinogens or psychedelics are strong psychoactive substances that act on the psychological state and influence the mood and several other processes in the brain. Among these, the use of the psychoactive natural substances has a long history in many cultures in sacred and religious rituals. Starting from the 1960s and 1970s, their popularity increased also as drugs of abuse. Serotoninergic hallucinogens include the classical psychedelic natural products containing N, N -dimethyltryptamine, psilocybin and psilocin, bufotenine, mescaline, lysergic acid amide, the synthetic hallucinogens as lysergic acid diethylamide, and the new hallucinogenic substances as tryptamine and phenethylamines derivatives, for which little is known regarding the toxicological properties and acute and chronic effects. This chapter provides a comprehensive update on serotoninergic hallucinogens, starting from their history and focusing on their classification, toxicokinetics, toxicodynamics, acute and chronic effects.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780323852159000222; http://dx.doi.org/10.1016/b978-0-323-85215-9.00022-2; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85128107424&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780323852159000222; https://api.elsevier.com/content/article/PII:B9780323852159000222?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:B9780323852159000222?httpAccept=text/plain; https://dul.usage.elsevier.com/doi/; https://dx.doi.org/10.1016/b978-0-323-85215-9.00022-2
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know